Show simple item record

dc.contributor.authorHertler, Magnus
dc.contributor.authorRudback, Thomas
dc.date.accessioned2010-06-22T09:08:23Z
dc.date.available2010-06-22T09:08:23Z
dc.date.issued2010-06-22
dc.identifier.urihttp://hdl.handle.net/2077/22652
dc.descriptionMSc in Intellectual Capital Managementsv
dc.description.abstractThe life science industry has experienced a large increase in size and convergence of traditional industries. This has resulted in a reduction of the space to operate for start-up biotech companies, and in innovative ways to solve the challenges. The purpose of the thesis is to investigate three aspects in relation to personalized medicine based on stem cells – the current patent landscape and how it affects market entry, the possibility of generating intellectual property rights in connection to the personalization aspect, as well as the commercial challenges and advantages these aspects have for biotech companies. This has been analyzed by conducting a case study of a start-up biotech company in combination with literature studies and discussions with professionals within the field. The outcome of the analysis shows that the current landscape creates great hurdles for biotech companies but that there still are good opportunities to reach market within the field for personalized medicine. Conclusions that can be drawn are that personalized medicine offers viable alternatives and that the role of intellectual property should not be underestimated.sv
dc.language.isoengsv
dc.relation.ispartofseriesMaster Degree Projectsv
dc.relation.ispartofseries2010:122sv
dc.titlePersonalized Medicine -a viable option for a biotech companysv
dc.typeText
dc.setspec.uppsokSocialBehaviourLaw
dc.type.uppsokH2
dc.contributor.departmentUniversity of Gothenburg/Graduate Schooleng
dc.contributor.departmentGöteborgs universitet/Graduate Schoolswe
dc.type.degreeMaster 2-years


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record